Ruxolitinib trial analysis explores response across patient subgroups
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies
What the study says
A pooled analysis of two phase 3 trials examined ruxolitinib cream outcomes across baseline patient characteristics. Among participants who used active cream from the start, 50.3% reached at least 75% improvement in facial VASI at one year. Responses were observed across demographic and clinical subgroups, including different skin phototypes and disease durations. This helps describe the range of participants represented in the trials. Because these were descriptive subgroup analyses, they should not be used to guarantee equal benefit or predict an individual person's response.
How to interpret this finding
Descriptive, post hoc analysis. Subgroup comparisons do not establish equal treatment effects.
Research findings describe groups of participants. Discuss their relevance to your own care with your clinician.
References & original sources
These links identify the actual paper, its indexed record and available full text.
Image source & reuse
Don Bliss (Illustrator) / National Cancer Institute
Context illustration: skin layers and melanocytes, from the National Cancer Institute. Not an image from the study.
View original image sourcePublic domain
